| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 12 Nov 2025 | 3 Nov 2025 |
| Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 inter alia to consider and approve This is to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday November 12 2025 inter alia to consider approve and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30 2025. Pursuant to Regulations 30 and 33 of the Listing Regulations, we submit herewith the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025, which were inter alia approved by the Board of Directors of the Company at their Meeting held today i.e., November 12, 2025, that commenced at 2.00 p.m. and concluded at 3.15 p.m (As Per Bse Announcement dated on 12/11/2025) | ||
| Board Meeting | 13 Aug 2025 | 7 Aug 2025 |
| Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 inter alia to consider and approve This is to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday August 13 2025 inter alia to consider approve and take on record the Unaudited Financial Results of the Company for the quarter ended June 30 2025. Unaudited Financial results for the quarter ended June 30, 2025 (As Per BSE Announcement Dated on: 13.08.2025) | ||
| Board Meeting | 19 May 2025 | 13 May 2025 |
| Dividend & Audited Results- Pfizer Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2025 ,inter alia, to consider and approve This is to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Monday, May 19, 2025 inter alia, to consider, approve and take on record the Audited Financial Results of the Company for the quarter and Financial Year ended March 31, 2025 and to consider recommendation of dividend, if any, for the Financial Year ended March 31, 2025. Outcome of Board Meeting The Board of Directors have recommended a final dividend of Rs. 35/- per equity share of Rs. 10/- each (350%) and a special dividend of Rs. 100/- per equity share of Rs. 10/- each (1000%) in view of 75th year of Pfizer in India and a special dividend of Rs. 30/- per equity share of Rs. 10/- each (300%) in view of the gain on transfer of assignment of leasehold land and building constructed on such land thereon, totaling to a dividend of Rs. 165/- per equity share Rs. 10/- each (1650%) for the financial year ended March 31, 2025. (As Per BSE Announcement Dated on:19.05.2025) | ||
| Board Meeting | 21 Feb 2025 | 21 Feb 2025 |
| Pursuant to the Regulation 30 of the Listing Regulations, we hereby inform that, the Board of Directors of the Company at their Meeting held today, that commenced on February 20, 2025 at 11.00 a.m. and concluded on February 21, 2025 at 1.45 p.m have approved a proposal today, to enter into a Marketing and Supply Agreement with Mylan Pharmaceuticals Private Limited for Marketing and Sale of two brands of the Company, viz., Ativan and Pacitane | ||
| Board Meeting | 31 Jan 2025 | 24 Jan 2025 |
| PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2025 inter alia to consider and approve Board Meeting to consider and take on record the Unaudited Financial Results for the quarter and nine months ended December 31 2024 Outcome of the Board Meeting- Unaudited Financial Results for the quarter and nine months ended December 31, 2024 (As Per BSE Announcement Dated on: 31/01/2025) | ||
Revenue also saw healthy growth. It was up 7.1% to ₹604 crore from ₹563 crore a year earlier.
Ativan is a common medication used predominantly for anxiety disorders, whereas Pacitane is used for Parkinson’s disease and other neurological conditions.
The agreement, which is discussed up to April and approved by Pfizer's Board of Directors, will be for five years, with discussions ending on 21 February 2025.
Revenue from operations decline marginally by 0.4% YoY at ₹538 crore, as against ₹540 crore in Q3 FY24
At the operating level, EBITDA increased by 60.2%, reaching ₹177.5 Crore in the first quarter of this fiscal year, compared to ₹110.8 Crore in the same quarter last year.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
